Analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Atyr PHARMA in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid ...

Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research note issued to ...

Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Outperform recommendation. As of January 29, 2025, the average one-year price ...

aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate ...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, aTyr Pharma (NASDAQ:ATYR) shareholders have done very well over the last year, with the share ...

aTyr Pharma, Inc. announced it will present three posters at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, showcasing its lead candidate efzofitimod ...